GSK Pharma receives Rs 3.54 cr demand notice from NPPA for overcharging

Regulatory & Legal View source PDF Explain this filing

GLAXO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.2%Reaction day

₹2370.00

prior close

₹2381.30

announcement price

In-mkt

timing

Nifty Midcap 150market-0.5%+0.4% vs market

Pharmaceuticals peers, median of 163sector-0.6%+0.5% vs sector

On the reaction day the stock moved 0.4 pts more than Nifty Midcap 150 and 0.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

-0.1

15m

-0.1

30m

-0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.2-0.5+0.4-0.6+0.5

Next day

-0.5-0.8+0.4-0.3-0.1

+3.4-0.4+3.8+0.4+3.0

+2.5-0.2+2.7+0.0+2.5

+1.6+0.3+1.3+0.2+1.4

+1.6+0.1+1.5+1.2+0.3

+1.6+0.2+1.4+0.1+1.5

15d

+3.6+0.4+3.2+0.8+2.8

+7.8+0.3+7.5+0.8+7.0

+26.9+2.9+24.0+1.2+25.7

+18.5-1.9+20.4+5.4+13.0

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 163Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

GSK Pharma received a demand notice from the National Pharmaceutical Pricing Authority (NPPA) on 24 June 2026 for alleged overcharging on scheduled formulations. Total demand is Rs 3.54 crore, comprising Rs 1.23 crore in alleged overcharging and Rs 2.31 crore in interest. The company has stated there is no material impact on its financial operations and intends to file an appeal against the demand order.

Likely market impact

Company says no material financial impact and plans to appeal. Amount is small relative to GSK Pharma's overall size.